文献速递肿瘤 PET/CT

18F-FDG PET/CT对混合型肝细胞-胆管癌的预后价值

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-05-02

该回顾性研究纳入46例治疗前接受FDG PET/CT的混合型肝细胞-胆管癌患者,以原发肿瘤TLR中位数3.4为截断值。中位随访29个月,29例(63.0%)复发或进展,25例(54.4%)死亡。多变量分析显示TLR是PFS(HR 5.19,95%CI 1.80-15.01;p=0.002)和OS(HR 3.95,95%CI 1.27-12.24;p=0.017)的独立预测因子。

要点

  • 治疗前原发肿瘤TLR>3.4与更大肿瘤尺寸(p=0.007)和更高肿瘤分期(p=0.030)相关。
  • TLR是PFS和OS的独立预测因子,高TLR患者2年PFS率17.8% vs 62.9%(p=0.001)。
  • 高TLR患者2年OS率39.1% vs 77.3%(p=0.001),预后显著更差。

核心结论

  • 治疗前FDG PET/CT测量的原发肿瘤TLR是cHCC-CC患者生存的独立预测因子。

研究设计与样本

  • 回顾性分析46例治疗前接受FDG PET/CT的cHCC-CC患者,以TLR中位数3.4为截断值。
  • 采用Cox比例风险回归模型评估TLR及其他临床变量的预后意义,Kaplan-Meier法比较PFS和OS。

主要发现

  • 中位随访29个月,29例(63.0%)出现肿瘤复发或进展,25例(54.4%)死于癌症。
  • TLR>3.4与更大肿瘤尺寸(p=0.007)和更高肿瘤分期(p=0.030)相关。
  • 单变量分析中TLR、肿瘤分期和CEA为显著预后预测因子。
  • 多变量分析中TLR是PFS(HR 5.19,95%CI 1.80-15.01;p=0.002)和OS(HR 3.95,95%CI 1.27-12.24;p=0.017)的独立预测因子。
  • 高TLR患者2年PFS率17.8% vs 62.9%(p=0.001),2年OS率39.1% vs 77.3%(p=0.001)。

关键数值与推荐

  • 以TLR中位数3.4作为高/低TLR的截断值。
  • TLR为原发肿瘤与正常肝脏的标准化摄取值比值(tumour-to-normal liver standardized uptake value ratio)。

临床怎么用

  • 治疗前FDG PET/CT测量的原发肿瘤TLR可用于cHCC-CC患者的生存风险分层。
  • TLR>3.4提示预后更差,可辅助临床治疗决策。

局限性

  • 回顾性研究,样本量46例,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) was assessed in patients with combined hepatocellular-cholangiocarcinoma (cHCC-CC). METHODS: A total of 46 patients with cHCC-CC who underwent FDG PET/CT before treatment were retrospectively analysed. Tumour FDG avidity was measured in terms of the tumour-to-normal liver standardized uptake value ratio (TLR) of the primary tumour on FDG PET/CT. The prognostic significance of TLR using the median value of 3.4 as the cut-off value and other clinical variables was assessed using Cox proportional hazards regression models. Differences in progression-free survival (PFS) and overall survival (OS) in relation to TLR were examined by the Kaplan-Meier method. RESULTS: During a median follow-up period of 29 months, 29 patients (63.0%) showed tumour recurrence or progression, and 25 patients (54.4%) died from cancer. Higher TLRs (>3.4) were associated with larger tumour size (p = 0.007) and higher tumour stage (p = 0.030). In a univariable analysis, TLR, tumour stage and CEA were significant prognostic predictors. In a multivariable analysis, TLR was an independent predictor of PFS (HR 5.19, 95% CI 1.80-15.01; p = 0.002) and OS (HR 3.95, 95% CI 1.27-12.24; p = 0.017). Patients with a higher TLR showed significantly worse PFS (2-year survival rate 17.8% vs. 62.9%; p = 0.001) and OS (2-year survival rate, 39.1% vs. 77.3%; p = 0.001) than those with a lower TLR. CONCLUSION: Pretreatment TLR of the primary tumour measured on FDG PET/CT is an independent predictor of survival in patients with cHCC-CC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lim CH, Moon SH, Cho YS, et al. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31049603. doi:10.1007/s00259-019-04327-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。